As MIG-7 is not expressed in normal ovarian tissues and is only detected during ovarian cancer development, MIG-7-targeted therapies should allow the specific inhibition of pathological angiogenesis associated with ovarian cancer development but spare physiological angiogenesis required for normal ovarian function. The gene discussed is BCAR3; the disease is ovarian cancer.